February 16, 2021
A New York federal judge granted Curaleaf's bid Tuesday to toss a proposed securities class action alleging that the cannabis chain caused a drop in its share prices by improperly marketing CBD products, finding that Curaleaf properly disclosed the disputed information about the products' legality.
June 05, 2020
A proposed class of investors in cannabis company Curaleaf has asked a New York federal judge not to dismiss its claims alleging the company caused share prices to fall by improperly marketing CBD products, saying Curaleaf understated the severity of the claims.
March 09, 2020
Cannabis company Curaleaf is urging a New York federal court to permanently end a "weak" investor suit alleging Curaleaf caused share prices to fall by improperly marketing its CBD products as drugs, arguing that its securities filings disclosed the risks it's accused of hiding.
November 06, 2019
A New York federal judge on Wednesday named Wolf Haldenstein Adler Freeman & Herz LLP as lead counsel in a consolidated investor lawsuit against cannabis company Curaleaf, after several firms initially placed bids to lead the litigation.
October 21, 2019
The lead counsel tussle in a proposed class action against cannabis giant Curaleaf Holdings Inc. has been winnowed down to two firms, with Levi & Korsinsky LLP and Wolf Haldenstein Adler Freeman & Herz LLP edging out four other competitors for the reins in a cannabidiol labeling stock drop case.
October 07, 2019
Pomerantz LLP and Wolf Haldenstein Adler Freeman & Herz LLP are among half a dozen law firms that sought on Friday to lead a proposed consolidated class action against Curaleaf Holdings Inc. for allegedly causing share prices to fall by improperly marketing its CBD products as drugs.